Artiva Biotherapeutics, Inc./$ARTV
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
- Ticker
- $ARTV
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 134
- Headquarters
- San Diego, United States
- Website
- www.artivabio.com
ARTV Metrics
BasicAdvanced
$196M
-
-$2.80
2.68
-
Price and volume
Market cap
$196M
Beta
2.68
52-week high
$14.53
52-week low
$2.96
Average daily volume
1.1M
Financial strength
Current ratio
19.883
Quick ratio
19.553
Long term debt to equity
0.018
Total debt to equity
0.029
Profitability
EBITDA (TTM)
-102.428
Management effectiveness
Return on assets (TTM)
-26.74%
Return on equity (TTM)
-43.61%
Valuation
Price to book
0.61
Price to tangible book (TTM)
0.61
Price to free cash flow (TTM)
-1.602
Free cash flow yield (TTM)
-62.41%
Free cash flow per share (TTM)
-2.472
Growth
Earnings per share change (TTM)
-13.73%
What the Analysts think about ARTV
Analyst ratings (Buy, Hold, Sell) for Artiva Biotherapeutics, Inc. stock.
Analyst projections of the future price of Artiva Biotherapeutics, Inc. stock.
ARTV Financial Performance
Revenues and expenses
ARTV Earnings Performance
Company profitability
Upcoming events
No upcoming events
ARTV News
AllArticlesVideos
Funds containing ARTV
Fund name | Fund size | $ARTV weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $4.7B | 0.00% |
SPDR Russell 2000 US Small Cap£R2SC | $4.7B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.